Drug Interaction Study of Sorafenib and Rapamycin in Advanced Malignancies

NCT00449280 | Completed Phase 1 DMC

• 1 other identifier: 14908B
• Study Type: interventional
• Target: 34
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this study is to determine whether a significant pharmacokinetic interaction exists between rapamycin and sorafenib. This study will also look at the toxicity of the combination of rapamycin and sorafenib and the antitumor activity of the combination in subjects with advanced cancers.

Conditions

Advanced Solid Tumor

Keywords

metastatic; advanced disease; phase I

Outcome Measures

Primary Outcomes (1)

• Pharmacokinetic interactions

  4 weeks

Secondary Outcomes (1)

• Response Rate

  8 weeks

Study Arms (4)

A

EXPERIMENTAL

Sorafenib two times a day every day for 28 days. Beginning on Day 15 (Week 2), rapamycin will be taken once a week until the end of the cycle (Day 28). After Day 28, weekly rapamycin and daily sorafenib will continue until disease progression or serious side effects are experienced.

Drug: Sorafenib; Drug: Rapamycin

B

EXPERIMENTAL

Sorafenib two times a day every day for 28 days. Beginning on Day 15 (Week 2), rapamycin will be taken every day until the end of the cycle (Day 28). After Day 28, rapamycin and sorafenib can continue to be taken daily until the cancer gets worse or serious side effects are experienced.

Drug: Sorafenib; Drug: Rapamycin

C

EXPERIMENTAL

Rapamycin once a week starting on Day 1. Beginning on Day 15 (Week 2), sorafenib will be taken twice a day every day until the end of the cycle (Day 28). After Day 28, weekly rapamycin and daily sorafenib will continue until disease progression or serious side effects are experienced.

Drug: Sorafenib; Drug: Rapamycin

D

EXPERIMENTAL

Rapamycin every day beginning on Day 1. Starting on Day 15 (Week 2), sorafenib will be taken twice a day every day until the end of the cycle (Day 28). After Day 28, rapamycin and sorafenib can continue to be taken daily until the cancer gets worse or serious side effects are experienced.

Drug: Sorafenib; Drug: Rapamycin

Interventions

Sorafenib DRUG

400mg BID (200 mg twice daily)

Also known as: Nexavar

A; B; C; D

Rapamycin DRUG

30mg once weekly

Also known as: Rapamune

A; C

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Solid cancer for which curative measures have failed or for which there is no known superior treatment
• ECOG performance status 0-2
• Measurable or non-measurable disease
• Life expectancy of greater than 12 weeks and no anticipated need for other antineoplastic therapy in the next 4 weeks
• Age 18 years or older
• Patients must have adequate organ and marrow function as defined below:
• ALT and AST less than or equal to 2.5 x the ULN (\< 5 x ULN for patients with liver involvement).
• hemoglobin greater than or equal to 9 g/dL
• absolute neutrophil count greater than or equal to 1,500/μL
• platelets greater than or equal to 100,000/μL (greater than or equal to 35,000/μL without transfusion for patients with CLL/SLL or follicular lymphoma)
• total bilirubin less than or equal to 1.5 x ULN
• creatinine less than or equal to 1.5 x ULN
• Women of childbearing potential must have a negative pregnancy test within 7 days of the start of treatment.
• Ability to understand and the willingness to sign a written informed consent document
• Must not have any evidence of bleeding diathesis.

You may not qualify if:

• Patients who have had chemotherapy or immunotherapy within 3 weeks or radiotherapy within 14 days prior to entering the study
• Patients may not be receiving any other investigational agents or any concomitant antineoplastic therapy
• Patients with uncontrolled brain metastases.
• HIV-positive patients receiving combination anti-retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with sorafenib or rapamycin.

Sponsors & Collaborators

• University of Chicago: lead
• Bayer: collaborator

Study Sites (1)

University of Chicago

Chicago, Illinois, 60637, United States

Location

MeSH Terms

Conditions

Neoplasm Metastasis

Interventions

Sorafenib; Sirolimus

Condition Hierarchy (Ancestors)

Neoplastic Processes; Neoplasms; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Phenylurea Compounds; Urea; Amides; Organic Chemicals; Benzene Derivatives; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Niacinamide; Nicotinic Acids; Acids, Heterocyclic; Heterocyclic Compounds; Pyridines; Heterocyclic Compounds, 1-Ring; Macrolides; Lactones

Study Officials

• Ezra Cohen, MD

  University of Chicago

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 16, 2007
• First Posted: March 20, 2007
• Study Start: November 1, 2006
• Primary Completion: June 1, 2009
• Study Completion: September 1, 2009
• Last Updated: June 12, 2013

Record last verified: 2013-06

Locations

US (1)